ZYME / Zymeworks Offers Hope for More than Just Long-Term Investors

VANCOUVER, British Columbia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, more_horizontal

VANCOUVER, British Columbia, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, more_horizontal

Zymeworks is a biotech company focused on developing therapies for hard-to-treat cancers. Its lead product, zanidatamab, has shown promising results i more_horizontal

Zymeworks Inc. (NASDAQ:ZYME ) Q2 2023 Earnings Call August 10, 2023 4:30 PM ET Company Participants Diana Papove - Director of Corporate Communication more_horizontal

Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss more_horizontal

VANCOUVER, British Columbia, July 03, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, more_horizontal

VANCOUVER, British Columbia, June 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, more_horizontal

Zymeworks Inc. (NASDAQ:ZYME ) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Kenneth Galbraith - Chairman, Chief Executi more_horizontal